Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas.

Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, Kofler J, Lu C, Tihan T, Sullivan LM, Santi M, Judkins AR, Perry A, Thompson CB.

J Neuropathol Exp Neurol. 2013 Apr;72(4):298-306. doi: 10.1097/NEN.0b013e3182898113.

2.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3.

PMID:
25427834
3.

[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].

Pan Y, Qi XL, Wang LM, Dong RF, Zhang M, Zheng DF, Chang Q, Zhong YF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002. Chinese.

PMID:
24004584
4.

CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JK, Wrensch MR, Walsh KM, Perry A.

J Neuropathol Exp Neurol. 2015 May;74(5):442-52. doi: 10.1097/NEN.0000000000000188.

5.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94.

6.

Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.

Ishizawa K, Hirose T, Sugiyama K, Kageji T, Nobusawa S, Homma T, Komori T, Sasaki A.

Clin Neuropathol. 2012 Mar-Apr;31(2):67-76.

PMID:
22385787
7.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Figarella-Branger D, Bouvier C, de Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P.

J Neurooncol. 2012 Nov;110(2):205-13. doi: 10.1007/s11060-012-0953-x.

PMID:
22890969
8.

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.

Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH.

Oncotarget. 2014 Sep 30;5(18):8083-92.

9.

Biomarker-driven diagnosis of diffuse gliomas.

Appin CL, Brat DJ.

Mol Aspects Med. 2015 Nov;45:87-96. doi: 10.1016/j.mam.2015.05.002. Review.

PMID:
26004297
10.

High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.

Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D, Hiemenz MC, Burns DK, White CL 3rd, Whitworth LA, Mickey B, Stegner M, Habib AA, Fink K, Maher EA, Bachoo RM.

J Neurooncol. 2014 Mar;117(1):183-9. doi: 10.1007/s11060-014-1376-7.

11.

Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.

Jentoft M, Giannini C, Rossi S, Mota R, Jenkins RB, Rodriguez FJ.

Am J Surg Pathol. 2011 Jun;35(6):845-52. doi: 10.1097/PAS.0b013e3182189693.

PMID:
21552114
12.

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Macaulay RJ.

Cancer Control. 2015 Apr;22(2):200-5. Review.

13.

Analysis of the IDH1 codon 132 mutation in brain tumors.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.

Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2.

PMID:
18985363
14.

WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.

Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, Schittenhelm J.

J Clin Pathol. 2014 Jul;67(7):556-61. doi: 10.1136/jclinpath-2013-202114.

PMID:
24607494
15.

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.

J Neurooncol. 2015 Sep;124(2):197-205. doi: 10.1007/s11060-015-1822-1.

PMID:
26033545
16.

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C.

Rev Neurol (Paris). 2011 Oct;167(10):683-90. doi: 10.1016/j.neurol.2011.07.006. Review.

PMID:
21889777
17.

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.

Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.

Acta Neuropathol. 2002 Mar;103(3):267-75.

PMID:
11907807
19.

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.

Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A.

Acta Neuropathol. 2011 Feb;121(2):241-52. doi: 10.1007/s00401-010-0770-2.

PMID:
21069360
20.

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.

Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA.

J Pathol. 2012 Jan;226(1):7-16. doi: 10.1002/path.2995.

Items per page

Supplemental Content

Support Center